Zota Health Care Q1 results: standalone profit, consolidated loss widens

Revenue growth above 20%Net loss reportedExceptional itemResults View source PDF Explain this filing

ZOTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.9%Reaction day

₹1260.00

prior close

₹1231.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-10.0% vs market

Pharmaceuticals peers, median of 166sector-0.4%-9.5% vs sector

On the reaction day the stock moved 10.0 pts less than Nifty Microcap 250 and 9.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.8

15m

-2.1

30m

-3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.9+0.1-10.0-0.4-9.5

Next day

-11.3+0.2-11.5-0.3-11.0

-13.9+0.6-14.5-0.5-13.4

-11.3-0.0-11.3-1.3-10.0

-14.5+0.5-15.0-0.8-13.7

-13.7+0.8-14.5-0.4-13.4

-14.3+0.6-14.9-0.9-13.5

15d

-10.3+1.3-11.6+0.0-10.4

-11.6-1.4-10.2-0.1-11.5

+12.8-0.6+13.4-2.8+15.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zota Health Care Q1 FY27 standalone revenue rose to Rs 12,702.91 lakhs (up 62.8% YoY) with PAT of Rs 163.82 lakhs vs a loss of Rs 34.60 lakhs last year. However, consolidated revenue of Rs 17,360.23 lakhs came with a steep loss of Rs 4,394.47 lakhs (vs Rs 1,446.19 lakhs loss) due to subsidiary losses. Auditors gave an unmodified review. Exceptional item of Rs 599.98 lakhs booked for new Labour Codes. Investments of about Rs 2,444 lakhs made in subsidiaries.

Likely market impact

Mixed: strong standalone turnaround but worsening consolidated losses from subsidiaries. Investors should watch Davaindia and other unit performance closely.